Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yescarta Becomes Japan’s Second Approved CAR-T

Other Nods For Alunbrig, Calquence, Emgality

Executive Summary

Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing. 

You may also be interested in...



Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.

Takeda On Continued Lookout For Assets After Recent Deals

Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel